Document 2630
 DOCN  M94A2630
 TI    Clinical outcome of HIV infection in children and survival due to early
       treatment by Retrovir.
 DT    9412
 AU    Rakhmanova A; Fomin Y; Chernykh M; Popova I; Voronin E; Vlasov N;
       Medical Academy of Postgraduate Education, Russian Clinical; HIV-AIDS
       Center, St.-Petersburg.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):260 (abstract no. PB0470). Unique
       Identifier : AIDSLINE ICA10/94369945
 AB    OBJECTIVE: A significant part of the HIV-AIDS epidemic has resulted from
       infections by the parenteral route. This route of infected has affected
       270 children in Russia. The aim was to describe the outcome in
       HIV-infected children and evaluate the survival dependent on the timing
       of Retrovir (Wellcome) treatment. METHODS: A cohort of 103 parenterally
       infected children were prospectively followed from Jan 1991 with
       periodic history, physical and laboratory assessment in Russian Clinical
       HIV-AIDS Center. RESULTS: In a significant proportion of parenterally
       infected children the disease developed within the first 3-4 months
       after the assumed time of exposure and these children experienced a more
       rapid progression to clinical AIDS. The rest continue to survive for
       longer periods of time. Of the 103 parenterally HIV-infected children 28
       (27.2%) developed AIDS three years after infection, 14 (13.6%) children
       with AIDS have died. Among HIV-infected children a broad spectrum of
       serious HIV- related diseases was observed. The common were severe
       Herpes simplex infection, mucocutaneous candidiasis, PCP. Less
       frequently found were LIP, disseminated cytomegalovirus infection,
       cryptosporidiasis, fungal infection of skin, hepatitis B. Children with
       the mostly unfavorable infection course were those who didn't receive
       the Retrovir treatment. CONCLUSION: Considering the progress of
       HIV-infection in children with AIDS developing during three years from
       the timing of parenteral infection it's recommended to begin the
       Retrovir treatment on from the diagnosis determination.
 DE    Acquired Immunodeficiency Syndrome/DRUG THERAPY/MORTALITY/  TRANSMISSION
       Child  Cohort Studies  Drug Administration Schedule  Follow-Up Studies
       Human  HIV Infections/*DRUG THERAPY/MORTALITY/TRANSMISSION  Prospective
       Studies  Russia  Survival Rate  Zidovudine/*ADMINISTRATION &
       DOSAGE/ADVERSE EFFECTS  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).